These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23422388)

  • 1. Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial.
    Czobor P; Volavka J; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychopharmacol; 2013 Apr; 33(2):258-61. PubMed ID: 23422388
    [No Abstract]   [Full Text] [Related]  

  • 2. Examining levels of antipsychotic adherence to better understand nonadherence.
    Remington G; Teo C; Mann S; Hahn M; Foussias G; Agid O
    J Clin Psychopharmacol; 2013 Apr; 33(2):261-3. PubMed ID: 23422390
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.
    Novick D; Haro JM; Suarez D; Perez V; Dittmann RW; Haddad PM
    Psychiatry Res; 2010 Apr; 176(2-3):109-13. PubMed ID: 20185182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients.
    Sapra M; Weiden PJ; Schooler NR; Sunakawa-McMillan A; Uzenoff S; Burkholder P
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):199-206. PubMed ID: 23428784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novelty seeking and medication adherence in patients with schizophrenia.
    Aukst Margetić B; Jakovljević M; Ivanec D; Tošić G; Margetić B
    Psychiatry Res; 2011 Mar; 186(1):141-3. PubMed ID: 20630601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAI-10 is as good as DAI-30 in schizophrenia.
    Nielsen RE; Lindström E; Nielsen J; Levander S
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):747-50. PubMed ID: 22440974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
    Kim J; Ozzoude M; Nakajima S; Shah P; Caravaggio F; Iwata Y; De Luca V; Graff-Guerrero A; Gerretsen P
    Neuropharmacology; 2020 May; 168():107634. PubMed ID: 31077729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.
    de Haan L; van Amelsvoort T; Dingemans P; Linszen D
    Pharmacopsychiatry; 2007 Nov; 40(6):264-8. PubMed ID: 18030650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia.
    Rasmussen H; Ebdrup BH; Aggernaes B; Lublin H; Oranje B; Pinborg LH; Knudsen GM; Glenthøj B
    J Clin Psychopharmacol; 2013 Apr; 33(2):266-9. PubMed ID: 23422401
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.
    Czobor P; Van Dorn RA; Citrome L; Kahn RS; Fleischhacker WW; Volavka J
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1158-66. PubMed ID: 26004980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.
    Volavka J; Van Dorn RA; Citrome L; Kahn RS; Fleischhacker WW; Czobor P
    Eur Psychiatry; 2016 Jan; 31():13-9. PubMed ID: 26657597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
    Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
    Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Arango C; Bernardo M
    Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome in males with first-episode schizophrenia: 7-year follow-up.
    Ceskova E; Prikryl R; Kasparek T
    World J Biol Psychiatry; 2011 Feb; 12(1):66-72. PubMed ID: 21087079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose versus low-dose strategies in the treatment of schizophrenia.
    Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M
    Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848
    [No Abstract]   [Full Text] [Related]  

  • 19. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
    Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
    J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia.
    Hayhurst KP; Drake RJ; Lewis SW
    J Psychopharmacol; 2010 Jan; 24(1):83-9. PubMed ID: 18719041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.